OMNIAB, INC. (OABI) Reports the reporting period Financial Results
OMNIAB, INC. (OABI) announced its financial results for the period ending the reporting period.
Key Financial Highlights:
Revenue: 15
Net Income: Not disclosed
EPS: Not disclosed
Cash and equivalents: 29046
stage clinical development, reinforcing the diversity and value of our portfolio. With a very strong start to the year, we are raising our 2026 revenue guidance,” stated Matt Foehr, Chief Executive Officer of OmniAb. “Continued progression of partner programs highlights the value of our technology platform and positions our business well for the future. Our innovation efforts continue to differentiate our platform as demonstrated by the launch of OmniUltra™ and our xPloration® partner access program.” First Quarter 2026 Financial ResultsRevenue for the first quarter of 2026 was $
4 million, compared with $
2 million for the same period in 2025, with the increase primarily related to milestone revenue. Research and development expense was $
expected in the second half of this year.•Potentially registrational studies with IMVT-1402
anticipated in the second or third quarter of 2026
expected in the second half of this year. Topline data from the proof-of-concept trial with IMVT-1402
📋 OMNIAB, INC. (OABI) - Financial Results
Filing Date: 2026-05-07
Accepted: 2026-05-07 16:13:37
Event Type: Financial Results
Event Details:
📊 Key Financial Metrics (Year-over-Year Comparison):
💼 Business Developments:
Structured Data: